Literature DB >> 3708908

Permanent large granular lymphocytosis in the blood of splenectomized individuals without concomitant increase of in vitro natural killer cell cytotoxicity.

E Kelemen, P Gergely, D Lehoczky, E Triska, J Demeter, P Vargha.   

Abstract

Increased numbers of circulating lymphocytes and large granular lymphocytes (LGL) were observed in 115 individuals splenectomized for haematological disease (74 cases) or for trauma (41 cases). LGL lymphocytosis was present in 78.4% of haematologically indicated and in 85.4% of traumatic splenectomies. A 70.5% of these values was above the 97.5 percentile upper tolerance limit of healthy controls (200 cases). In addition, 175 haematological controls were investigated. Forty per cent or more of circulating lymphocytes exhibited LGL morphology in nearly half of repeatedly investigated splenectomized persons. The increase in LGL is not attributable to lymphocytosis. It becomes apparent, and persists after the first postoperative week, irrespective of the cause of surgery. In spite of the two-fold increase in LGL concentration in the blood, in vitro natural killer (NK) and antibody dependent cellular cytotoxic (ADCC) activities did not increase in the investigated 48 (NK) and 31 (ADCC) splenectomized persons, as compared with the appropriate healthy or haematological controls.

Entities:  

Mesh:

Year:  1986        PMID: 3708908      PMCID: PMC1577547     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  14 in total

Review 1.  Morphological and functional characterization of isolated effector cells responsible for human natural killer activity to fetal fibroblasts and to cultured cell line targets.

Authors:  E Saksela; T Timonen; A Ranki; P Häyry
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

2.  Effect of histamine receptor blocking on human antibody-dependent cell-mediated cytotoxicity.

Authors:  I Láng; K Török; P Gergely; K Nékám; G Petrányi
Journal:  Scand J Immunol       Date:  1981       Impact factor: 3.487

3.  Natural killer cell activity and T subpopulations in thalassemia major.

Authors:  A Neri; M Brugiatelli; P Iacopino; V Callea; F Ronco
Journal:  Acta Haematol       Date:  1984       Impact factor: 2.195

Review 4.  Definition of the cell types within the "null lymphocyte" population of human peripheral blood: an analysis of phenotypes and functions.

Authors:  M Ferrarini; C E Grossi
Journal:  Semin Hematol       Date:  1984-10       Impact factor: 3.851

5.  Monocyte antibody-dependent cellular cytotoxicity in splenectomized subjects.

Authors:  P G Gill; N J De Young; G K Kiroff; P I Leppard; G McLennan
Journal:  J Immunol       Date:  1984-03       Impact factor: 5.422

6.  Separation of lymphocytes from peripheral blood: a revisitation.

Authors:  O McKeating; H D Alexander; G M Markey; T C Morris
Journal:  J Clin Pathol       Date:  1985-05       Impact factor: 3.411

7.  Human large granular lymphocytes and their relationship to natural killer cell activity in various disease states.

Authors:  G Gastl; D Niederwieser; C Marth; H Huber; D Egg; G Schuler; R Margreiter; H Braunsteiner; C Huber
Journal:  Blood       Date:  1984-07       Impact factor: 22.113

8.  Surface markers on human b and t lymphocytes. VI. Cytotoxicity against cell lines as a functional marker for lymphocyte subpopulations.

Authors:  M Jondal; H Pross
Journal:  Int J Cancer       Date:  1975-04-15       Impact factor: 7.396

9.  Capacity of human large granular lymphocytes (LGL) to produce multiple lymphokines: interleukin 2, interferon, and colony stimulating factor.

Authors:  T Kasahara; J Y Djeu; S F Dougherty; J J Oppenheim
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

10.  Characteristics of human large granular lymphocytes and relationship to natural killer and K cells.

Authors:  T Timonen; J R Ortaldo; R B Herberman
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

View more
  7 in total

1.  Increase in CD57 + CD16-lymphocytes in workers exposed to benzidine and beta-naphthylamine: assessment of natural killer cell subpopulations.

Authors:  T Tanigawa; S Araki; T Abo; S Sakurai
Journal:  Int Arch Occup Environ Health       Date:  1996       Impact factor: 3.015

2.  A case presenting with rapid renal damage caused by immunoglobulin D lambda-type multiple myeloma accompanied by granular lymphocyte proliferative disorder.

Authors:  Naro Ohashi; Kosuke Hirota; Akashi Togawa; Nobuharu Kosugi; Kunio Ohyama
Journal:  Clin Exp Nephrol       Date:  2011-03-03       Impact factor: 2.801

3.  T-cell large granular lymphocytic leukemia: 4 cases.

Authors:  Anila Rashid; Mohammad Khurshid; Arsalan Ahmed
Journal:  Blood Res       Date:  2014-09-25

4.  Abnormal NK cell lymphocytosis detected after splenectomy: association with repeated infections, relapsing neutropenia, and persistent polyclonal B-cell proliferation.

Authors:  Elisa Granjo; Margarida Lima; Manuela Fraga; Filipe Santos; Conceição Magalhães; Maria Luís Queirós; Ilidia Moreira; Sandra Rocha; Alice Santos Silva; Irene Rebelo; Alexandre Quintanilha; Maria Letícia Ribeiro; Jorge Candeias; Alberto Orfão
Journal:  Int J Hematol       Date:  2002-06       Impact factor: 2.490

5.  A screening method with lymphocyte percentage and proportion of granular lymphocytes in the peripheral blood for large granular lymphocyte (LGL) leukemia.

Authors:  Takahiro Tanahashi; Nodoka Sekiguchi; Kazuyuki Matsuda; Akihiro Matsumoto; Toshiro Ito; Hideyuki Nakazawa; Fumihiro Ishida
Journal:  Int J Hematol       Date:  2016-09-29       Impact factor: 2.490

Review 6.  Metronomic regimen as an effective treatment for aggressive T-LGL leukemia with central nervous system infiltration: clinical experience and review of literature.

Authors:  Yun Liu; Lei Fan; Huihui Zhao; Wei Xu; Jianyong Li
Journal:  Oncotarget       Date:  2017-05-09

Review 7.  Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias.

Authors:  Kazuo Oshimi
Journal:  Intern Med       Date:  2017-07-15       Impact factor: 1.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.